107 related articles for article (PubMed ID: 27453282)
21. JNK and p53 stress signaling cascades are altered in MCF-7 cells resistant to tumor necrosis factor-mediated apoptosis.
Doman RK; Perez M; Donato NJ
J Interferon Cytokine Res; 1999 Mar; 19(3):261-9. PubMed ID: 10213465
[TBL] [Abstract][Full Text] [Related]
22. From biochemical principles of apoptosis induction by TRAIL to application in tumour therapy.
Cordier SM; Papenfuss K; Walczak H
Results Probl Cell Differ; 2009; 49():115-43. PubMed ID: 19142621
[TBL] [Abstract][Full Text] [Related]
23. Bigelovin inhibits STAT3 signaling by inactivating JAK2 and induces apoptosis in human cancer cells.
Zhang HH; Kuang S; Wang Y; Sun XX; Gu Y; Hu LH; Yu Q
Acta Pharmacol Sin; 2015 Apr; 36(4):507-16. PubMed ID: 25619393
[TBL] [Abstract][Full Text] [Related]
24. BI2536--A PLK inhibitor augments paclitaxel efficacy in suppressing tamoxifen induced senescence and resistance in breast cancer cells.
Prashanth Kumar BN; Rajput S; Bharti R; Parida S; Mandal M
Biomed Pharmacother; 2015 Aug; 74():124-32. PubMed ID: 26349973
[TBL] [Abstract][Full Text] [Related]
25. Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response.
Lagneaux L; Gillet N; Stamatopoulos B; Delforge A; Dejeneffe M; Massy M; Meuleman N; Kentos A; Martiat P; Willems L; Bron D
Exp Hematol; 2007 Oct; 35(10):1527-37. PubMed ID: 17697742
[TBL] [Abstract][Full Text] [Related]
26. Is TRAIL the holy grail of cancer therapy?
Newsom-Davis T; Prieske S; Walczak H
Apoptosis; 2009 Apr; 14(4):607-23. PubMed ID: 19194800
[TBL] [Abstract][Full Text] [Related]
27. Novel TRAIL sensitizer Taraxacum officinale F.H. Wigg enhances TRAIL-induced apoptosis in Huh7 cells.
Yoon JY; Cho HS; Lee JJ; Lee HJ; Jun SY; Lee JH; Song HH; Choi S; Saloura V; Park CG; Kim CH; Kim NS
Mol Carcinog; 2016 Apr; 55(4):387-96. PubMed ID: 25647515
[TBL] [Abstract][Full Text] [Related]
28. Parthenolide reverses doxorubicin resistance in human lung carcinoma A549 cells by attenuating NF-κB activation and HSP70 up-regulation.
Xin Y; Yin F; Qi S; Shen L; Xu Y; Luo L; Lan L; Yin Z
Toxicol Lett; 2013 Aug; 221(2):73-82. PubMed ID: 23792430
[TBL] [Abstract][Full Text] [Related]
29. Ilimaquinone induces death receptor expression and sensitizes human colon cancer cells to TRAIL-induced apoptosis through activation of ROS-ERK/p38 MAPK-CHOP signaling pathways.
Do MT; Na M; Kim HG; Khanal T; Choi JH; Jin SW; Oh SH; Hwang IH; Chung YC; Kim HS; Jeong TC; Jeong HG
Food Chem Toxicol; 2014 Sep; 71():51-9. PubMed ID: 24930757
[TBL] [Abstract][Full Text] [Related]
30. Clinical trials referral resource. Clinical trials of MGI-114.
Murgo A; Cannon DJ; Blatner G; Cheson BD
Oncology (Williston Park); 1999 Feb; 13(2):233, 237-8. PubMed ID: 10079472
[No Abstract] [Full Text] [Related]
31. Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase.
Wu CP; Hsieh YJ; Hsiao SH; Su CY; Li YQ; Huang YH; Huang CW; Hsieh CH; Yu JS; Wu YS
Mol Pharm; 2016 Mar; 13(3):784-94. PubMed ID: 26796063
[TBL] [Abstract][Full Text] [Related]
32. Regulation of death receptors--relevance in cancer therapies.
de Thonel A; Eriksson JE
Toxicol Appl Pharmacol; 2005 Sep; 207(2 Suppl):123-32. PubMed ID: 16126242
[TBL] [Abstract][Full Text] [Related]
33. Targeting stem cell signaling pathways for drug discovery: advances in the Notch and Wnt pathways.
An SM; Ding Q; Zhang J; Xie J; Li L
Sci China Life Sci; 2014 Jun; 57(6):575-80. PubMed ID: 24829106
[TBL] [Abstract][Full Text] [Related]
34. CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells.
Llobet D; Eritja N; Encinas M; Llecha N; Yeramian A; Pallares J; Sorolla A; Gonzalez-Tallada FJ; Matias-Guiu X; Dolcet X
Oncogene; 2008 Apr; 27(18):2513-24. PubMed ID: 17982483
[TBL] [Abstract][Full Text] [Related]
35. TRAIL and targeting cancer cells: between promises and obstacles.
Limami Y; Pinon A; Riaz A; Simon A
Cell Mol Biol (Noisy-le-grand); 2015 Oct; 61(6):33-8. PubMed ID: 26518894
[TBL] [Abstract][Full Text] [Related]
36. Natural products are the future of anticancer therapy: Preclinical and clinical advancements of Viscum album phytometabolites.
Attar R; Tabassum S; Fayyaz S; Ahmad MS; Nogueira DR; Yaylim I; Timirci-Kahraman O; Kucukhuseyin O; Cacina C; Farooqi AA; Ismail M
Cell Mol Biol (Noisy-le-grand); 2015 Oct; 61(6):62-8. PubMed ID: 26518897
[TBL] [Abstract][Full Text] [Related]
37. Understanding of tolerance in TRAIL-induced apoptosis and cancelation of its machinery by α-mangostin, a xanthone derivative.
Kumazaki M; Shinohara H; Taniguchi K; Ueda H; Nishi M; Ryo A; Akao Y
Oncotarget; 2015 Sep; 6(28):25828-42. PubMed ID: 26304927
[TBL] [Abstract][Full Text] [Related]
38. Feedback regulation in cell signalling: Lessons for cancer therapeutics.
Nguyen LK; Kholodenko BN
Semin Cell Dev Biol; 2016 Feb; 50():85-94. PubMed ID: 26481970
[TBL] [Abstract][Full Text] [Related]
39. Cytoprotective and regulatory functions of glutathione S-transferases in cancer cell proliferation and cell death.
Singh S
Cancer Chemother Pharmacol; 2015 Jan; 75(1):1-15. PubMed ID: 25143300
[TBL] [Abstract][Full Text] [Related]
40. NO signaling confers cytoprotectivity through the survivin network in ovarian carcinomas.
Engels K; Knauer SK; Loibl S; Fetz V; Harter P; Schweitzer A; Fisseler-Eckhoff A; Kommoss F; Hanker L; Nekljudova V; Hermanns I; Kleinert H; Mann W; du Bois A; Stauber RH
Cancer Res; 2008 Jul; 68(13):5159-66. PubMed ID: 18593915
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
